OncLive

OncLive® serves as the official platform for the Oncology Specialty Group, which produces publications such as OncologyLive, Oncology Fellows, and Oncology Nursing News. The goal of OncLive® and its associated publications is to equip oncology professionals with essential resources and information to enhance patient care. Additionally, OncLive® features video programs like Peer Exchange, Insights, and News Network, offering engaging discussions filled with expert insights, opinions, and viewpoints on critical topics relevant to today's cancer care experts.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#290032

United States

#120428

Health/Health Conditions and Concerns

#279

Traffic sources

Monthly visitors

Articles

IMA203 Demonstrates Early Promise in PD-1-Refractory Metastatic Melanoma

2 days ago | onclive.com | Kristi Rosa

The PRAME-directed TCR T-cell therapy IMA203 displayed acceptable tolerability and showcased early clinical activity in patients with PD-1–refractory metastatic melanoma, according to data from a phase 1 study (NCT03686124) presented during the 2025 ASCO Annual Meeting.1With regard to safety, the trial’s primary end point, the most common treatment-emergent adverse effects (TEAEs) were anticipated cytopenias linked with lymphodepleting chemotherapy.
Highlighting the Key Takeaways From ASH 2024

2 days ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s):,Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy, bispecifics, and minimal residual disease (MRD) monitoring are reshaping lymphoma treatment strategies, with emerging data showing promising outcomes for various lymphoma subtypes and ongoing trials exploring optimal sequencing of these therapies.
Treatment and Management of MM with Amyloidosis

2 days ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s):,Panelists discuss how insights from ASH 2024 are shaping the treatment and management of multiple myeloma (MM) with amyloidosis, emphasizing early diagnosis, novel therapies, and personalized treatment strategies to improve patient outcomes.
Recommendations For Future Clinical Trials in R/R MM

2 days ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s):,Panelists discuss how insights from ASH 2024 highlight the need for personalized treatment strategies, improved trial designs, and greater inclusion of diverse patient populations in future clinical trials for relapsed/refractory multiple myeloma (R/R MM).
Annamycin Drives Clinical Benefit in Soft Tissue Sarcoma Lung Metastases

3 days ago | onclive.com |

The next-generation anthracycline analog annamycin demonstrated clinical activity and a favorable safety profile in patients with soft tissue sarcoma and lung metastases, according to updated findings from the phase 1b/2 MB-107 trial (NCT04887298).1In the study population evaluable for efficacy (n = 36), the clinical benefit rate (CBR) was 59.4%, comprising 18 patients who achieved stable disease and 1 patient who experienced a partial response.
Accelerated FDA Approval Establishes Role of Avutometinib/Defactinib in KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer

3 days ago | onclive.com |

The FDA accelerated approval of avutometinib in combination with defactinib (Avmapki Fakzynja Co-pack) represents a significant step forward in the treatment of patients with KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC), according to Rachel Grisham, MD.
NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis

4 days ago | onclive.com | Caroline Seymour

The BCMA-directed CAR T-cell therapy NXC-201 led to fast-onset responses that proved durable and were characterized by low-grade cytokine release syndrome (CRS) and no neurotoxicity in patients with relapsed/refractory light chain (AL) amyloidosis, according to initial data from the phase 1/2 NEXICART-2 trial (NCT06097832) that were presented at the 2025 ASCO Annual Meeting.1 At a median follow-up of 121 days (range, 29-289), the percentage change in the difference between the involved and...
Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600-Mutant Melanoma

4 days ago | onclive.com | Ashley Chan

Encorafenib (Braftovi) added to binimetinib (Mektovi) was generally well tolerated and demonstrated the potential for adjuvant BRAF/MEK inhibition to reduce recurrence risk in patients with high-risk, stage IIB/C BRAF V600–mutant melanoma, according to data from the primary analysis of the phase 3 EORTC-2139-MG/Columbus-AD trial (NCT05270044) presented at the 2025 ASCO Annual Meeting.1 In the intention-to-treat (ITT) population (n = 110), the 12-month recurrence-free survival (RFS) rates were...
Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

4 days ago | onclive.com | Ashley Chan

An exploratory circulating tumor DNA (ctDNA) analysis from the phase 3 CALLA trial (NCT03830866) showed that the risk of disease progression or death was reduced by at least 95% in patients with locally advanced cervical cancer treated with durvalumab (Imfinzi) plus chemoradiotherapy (CRT) or CRT plus placebo alone who had undetectable ctDNA at the start of cycle 6. Additionally, low ctDNA at baseline was associated with improved survival outcomes in both arms compared with high ctDNA.
Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma

4 days ago | onclive.com | Tim Cortese

The addition of daratumumab (Darzalex) to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) improved rates of minimal residual disease (MRD) negativity vs KRd alone in patients with newly diagnosed multiple myeloma, independent of transplant eligibility, according to findings from the phase 2 ADVANCE trial (NCT04268498) presented at the 2025 ASCO Annual Meeting.1 In the intention-to-treat population, MRD negativity at a threshold of 10–5 assessed by next-generation...